to address both dupilumab-responsive and refractory disorders, such as hypereosinophilic syndrome (HES). This mechanism establishes AK139 as a possible paradigm-shifting therapy for complicated type 2 ...

Notably, the first FDA-approved biologic was dupilumab (Dupixent; Regeneron, Sanofi), and this approval took place less than 1 year ago in September 2024. Khavandi: Inhaled therapy — viewed as a ...

Understand Parkinson's disease, its symptoms, and the crucial role of clinical trials in treatment and research, especially for Black Americans.